Dyax Corp. Given Average Recommendation of “Buy” by Analysts (NASDAQ:DYAX)
Shares of Dyax Corp. (NASDAQ:DYAX) have earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, Stock Ratings Network reports. Five research analysts have rated the stock with a buy rating, The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.14.
DYAX has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $7.00 to $8.00 in a research note on Wednesday. Separately, analysts at Bank of America reiterated a “positive” rating on shares of Dyax Corp. in a research note on Wednesday, May 28th. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Dyax Corp. in a research note on Saturday, May 17th. They now have a $9.00 price target on the stock.
Shares of Dyax Corp. (NASDAQ:DYAX) opened at 9.15 on Wednesday. Dyax Corp. has a one year low of $3.87 and a one year high of $10.99. The stock has a 50-day moving average of $8.96 and a 200-day moving average of $8.47. The company’s market cap is $1.243 billion.
Dyax Corp. (NASDAQ:DYAX) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $19.59 million for the quarter, compared to the consensus estimate of $14.13 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was up 72.9% on a year-over-year basis. On average, analysts predict that Dyax Corp. will post $-0.19 earnings per share for the current fiscal year.
Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.
Receive News & Ratings for Dyax Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyax Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.